Showing posts with label weekend reading. Show all posts
Showing posts with label weekend reading. Show all posts

Sunday, January 27, 2019

Hepatitis Stigma: Barriers To Treatment - Burden Of Disclosure

Stigma and Discrimination 
Welcome to weekend reading, its a cold Sunday here in Michigan, hope its warmer in your part of the world. Today we have an article and podcast for the people of Australia, covering the negative impact of stigma and discrimination associated with the hepatitis C virus (HCV). 

Barriers To Treatment 
Let's start with a review of an Australian study published in PLOS One over at NAM, titled: Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins, written by Keith Alcorn. According to the PLOS One study, based on patient interviews, some participants reported they were treated poorly by health care professionals, for instance, physicians and pharmacists. An excerpt for the study; 

Finding supportive and non-judgmental care
Participants discussed their experiences of stigma and discrimination in health care settings. Examples included emergency doctors telling participants they ‘were sick of dealing with you junkies’ (male, group 3, 34 years) and pharmacists making participants wait for lengthy periods before being served, speaking to them in a poor manner and generally not observing common courtesies to customers with injecting histories. Often, discussion of stigma centred around participants’ sense that clinicians viewed them as inappropriate clients to be receiving DAA treatment, which resulted in the internalization of these messages. 
I still hide it, no matter what… I just won’t do it…um, and yeah that’s from fear of judgment I’d say but I don’t think it would have really mattered. It’s more from me… it’s the stigma within as much as the stigma without. (male, group 4, 56 years)
Read the patient-friendly article here, study here.
Follow NAM on Twitter, connect on Facebook, or sign up for Email updates.

New Podcast - Burden Of Disclosure

Over at Hepatitis Victoria, Judith Gorst, a practice nurse and counsellor, talks about stigma and discrimination surrounding blood-borne infections; especially when disclosing status to friends, family and health care professionals. Listen below or here: Stigma & healthcare: Should you disclose your hepatitis status?

Listen To All Podcasts
Viral Hepatitis Playlist: Hepatitis Victoria

Hepatitis Victoria - Stigma and Discrimination

Unfortunately, people knowing, or thinking, you have hepatitis B and/or hepatitis C, can mean they treat you differently to other people. This can be distressing, and contribute to internal feelings of shame or other unpleasant feelings. It can also have a real effect on your social experiences, including the services you are provided with, and the quality of those services.

We aim to give you more information about stigma and discrimination: what it means; when you have to disclose you have hepatitis B and/or C; what your rights are if someone has treated you poorly; and, issues to consider if you work with people who have hepatitis B and/or C. 

Thanks for stopping by!

Saturday, March 10, 2018

Patient To Patient Video - Treating HCV according to genotype with a focus on HCV genotype 3

Patient To Patient Video 
Happy Saturday folks, here is a new patient friendly video launched by Hepatitis C activist Greg Jefferys, with a look at current therapies used to treat the hepatitis C virus across all HCV genotypes.

Generic Hepatitis C Drugs
Greg is the founder of Hepatitis C Buyers Club, formed to help people buy generic Harvoni or Epclusa. Visit his website and watch treatment videos, learn about symptoms or possible treatment side effect. Finally, make sure to read Greg's latest articles over at HepMag.

On This Blog
2018 HCV Genotypes and Treatment
Offered on this page is research updates with a focus on treating HCV according to genotype using FDA approved and investigational medicines. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities.

Drugs Used To Treat Hep C
The following HCV Guidelines offer treatment recommendations using current HCV medications based on HCV Genotype and history of treatment. Which include treatment-naive patients (patients who have never used HCV medications to treat the virus) and treatment-experienced patients (patients who have previously taken HCV medications).

The following pages include guidance for management of treatment-naive patients.
Genotype 1
Genotype 2
Genotype 3
Genotype 4
Genotype 5 or 6

The following pages include guidance for management of treatment-experienced patients.
Genotype 1
Genotype 2
Genotype 3
Genotype 4
Genotype 5 or 6

Stay current with all guideline updates, "click here."

Enjoy your weekend, thank you Mr. Jefferys!

Sunday, October 1, 2017

Weekend Reading - Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C – A Review

Weekend Reading
Greetings, hope you're enjoying this lovely Sunday, thanks for stopping by.

Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
We begin with a recent review article about Gilead's Vosevi, titled; “Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C – A Review” published September 22, 2017, in Gastroenterology & Hepatology.

HCV Genotype 3
Over at NEJM Journal Watch, a small study for HCV genotype 3 patients is reviewed by Atif Zaman, MD, MPH, published last week in Hepatology. The study; Glecaprevir/pibrentasvir for HCV genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase III clinical trial, is available for download over at NATAP

New Online
Make sure to check out HCV Advocate's October Newsletter, published today!

Shared on Twitter, by @HenryEChang, is one must read article: Chronic hepatitis C virus infection: Everyone should be treated, published in the multimedia journal Clinical Liver Disease. Here are a few other updates over at CLD as well.

Reviews - Controversies in HCV Management
Chronic hepatitis C virus infection: Everyone should be treated
Authors Steven Flamm
First Published: 29 September 2017
Full Text (HTML)
PDF (91.3KB)
PDF (91.3KB)
Watch a video presentation of this article
Watch the interview with the author

Reviews - Controversies in HCV Management
Authors Philippe J. Zamor, Mark W. Russo
First Published: 29 September 2017

Reviews - From Operation to the First 30 Days
Innovative care models after liver transplant
Authors C. Burcin Taner, Andrew P. Keaveny
First Published: 29 September 2017
Full Text (HTML)
PDF (217.7KB)
PDF (217.7KB)
Watch a video presentation of this article
Watch the interview with the author

Begin here...

Enjoy the rest of your weekend!

Saturday, August 26, 2017

How To Watch - First in Human: Real-life experiences of doctors, patients and researchers of NIH Clinical Center

How To Watch - First in Human

Welcome to this issue of "Weekend Reading," if you missed the new Discovery documentary "First in Human" about cutting-edge research taking place at the "National Institutes of Health’s Clinical Center," watch past and current episodes on either your TV (if you have on demand) or a favorite device by logging into your TV provider (cable or satellite company); list provided further down this page.

Documentary Background
Narrated by Jim Parsons, "First in Human" is a look at real-life stories of patients, researchers, and physicians who participate in clinical trials at the National Institutes of Health’s Clinical Center. NIH Clinical Center is the Nation's largest hospital devoted to clinical research, medical research that is saving and improving lives, and laying the groundwork for drugs used to cure devastating diseases.

Start by reading about America's first government-run hospital: "NIH Clinical Center," or review additional information about the "program," and just for fun, watch Jim Parsons on "Jimmy Kimmel" explain why he took part in the documentary.

Hepatitis C The NIH Connection 
In 1999, as a hepatitis C patient, I jumped into the pool of clinical trials, swimming around until I was completely cured. Rather you or a loved one have benefited from taking part in a clinical trial, or directly from medical research, we all have, know that you will be deeply moved by this awe inspiring documentary.

Did You Know?
In the mid-20th century across the United States, patients were contracting Hepatitis following blood transfusions. Researchers in the Clinical Center Blood Bank, led by Harvey Altar, developed lifesaving tests that screened for Hepatitis B in the blood supply and led to the virtual elimination of cases in which patients contracted Hepatitis B through blood transfusions. The same researchers working in the Clinical Center along with others working outside of NIH also eventually identified Hepatitis C and a test for screening for Hepatitis C in blood banks.....
History of NIH Clinical Center 

First in Human: The Trials of Building 10
On July 6, 1953, the NIH Clinical Center welcomed its first patient, Charles Meredith, a Maryland farmer. Meredith arrived at the Clinical Center to participate in a study on hormone treatments for prostate cancer. His admission to the Clinical Center was the start of a unique research effort by the Federal government.....

Discovery Documentary First in Human
First in Human is a three-part documentary capturing the real-life experiences of doctors, researchers, staff, patients and their caregivers, at the NIH Clinical Center. 
The documentary airs on three sequential Thursday evenings on August 10, 17, and 24, at 9:00 p.m. ET/PT on Discovery.
For over a year, Discovery, in collaboration with John Hoffman (Weight of the Nation, Sleepless in America), was embedded in the NIH Clinical Center to capture the challenges faced in diagnosing and treating diseases.
Narrated by Jim Parsons (Big Bang Theory, Hidden Figures), the three-episode series showcases the innovative work that takes place within the NIH Clinical Center and provides an in-depth look at the reality of experimental medicine in clinical trials.
Continue reading...

Jim Parsons on Jimmy Kimmel
Published on Aug 10, 2017

Watch Live
Click on an episode (sign in key) and pick your provider.

Sign in with your TV provider to stream the program, here is a list of providers.

3 Rivers Communications
Access Montana
Acme Communications
Adams Cable Service
Advanced Cable Communications
Albany Mutual Telephone
Algona Municipal Utilities
All West Communications
Allen's Communications
Alliance Communications
ALLO Communications
Alpine Communications
American Broadband
American Broadband Missouri
American Community Networks
American Warrior Networks
Amherst Telephone/Tomorrow Valley
Arkwest Communications
Arthur Mutual Telephone Company
Ashland Home Net
AT&T U-Verse
ATC Broadband
ATC Communications
Atlantic Broadband
Ayersville Communications
Baldwin Telecom, Inc.
Ballard TV
Bardstown Cable TV
Bay Country Communications
Beach Cable
Beaver Creek Cooperative Telephone
Beaver Valley Cable
Bee Line Cable
Beehive Broadband
BEK Communications
Bellevue Municipal Cable
Ben Lomand Connect / BLTV
Benton Cablevision
Big Sandy Broadband
Bledsoe Telephone Cooperative
Blue Ridge Communications
Blue Stream
Blue Valley Tele-Communications
Brandenburg Telephone Co.
Bristol Tennessee Essential Services
BTC Communications
BTC Vision - Nahunta
Buckeye Broadband
Bulloch Telephone Cooperative
Burlington Telecom
Butler-Bremer Communications
BVU Optinet
C Spire
C Spire SNAP
Cable ONE
Cable Services Inc.
Cable TV of East Alabama
CableSouth Media 3
Cam-Tel Company
Camellia Communication - Hayneville Telephone
Cameron Communications
CapRock Tv
Carnegie Cable
Carolina Mountain Cablevision
CAS Cable
Catalina Broadband Solutions
CC Communications
CDE Lightband
Cedar Falls Utilities
Celect-Bloomer Telephone Area
Celect-Bruce Telephone Area
Celect-Citizens Connected Area
Celect-Elmwood/Spring Valley Area
Celect-Mosaic Telecom
Celect-West WI Telephone Area
Central Arkansas Telephone Cooperative
Central Scott / CSTV
CenturyLink Prism
Chariton Valley Communication Corporation, Inc.
Charter | Spectrum
Chatmoss Cablevision
Cherokee Communications
Chesapeake Bay Communications
Chesnee Communications
Cim-Tel Cable LLC
Cincinnati Bell Fioptics
Citizens Cablevision - Floyd, VA

Saturday, July 22, 2017

Weekend Reading - The "liver to-do list."

Welcome to "Weekend Reading" folks, thank you for stopping by.

One of my biggest obsessions, well, other than my family, is reading a great article about the liver, you too? For me it all started when I was diagnosed with HCV, today I am cured but never pass up a good read devoted to this fascinating organ.

Somehow I missed; The Liver: A ‘Blob’ That Runs the Body, written by Natalie Angier, published last month over at the New York Times website. If you haven't had a chance to read the article yet, you're in for a treat, here is a brief look:
After all, a healthy liver is the one organ in the adult body that, if chopped down to a fraction of its initial size, will rapidly regenerate and perform as if brand-new. Which is a lucky thing, for the liver’s to-do list is second only to that of the brain and numbers well over 300 items, including systematically reworking the food we eat into usable building blocks for our cells; neutralizing the many potentially harmful substances that we incidentally or deliberately ingest; generating a vast pharmacopoeia of hormones, enzymes, clotting factors and immune molecules; controlling blood chemistry; and really, we’re just getting started.
 Continue reading.....

Saturday, March 25, 2017

Hep C Weekend Reading: Favorite quote of the week “Fight to treat your patients as early as possible.”

HCV Weekend Reading
Hope you all had a wonderful week, sit back and catch up on what you may have missed over the last week in this issue of Weekend Reading.

In a recent article published in Clinical Infectious Diseases, data suggested that delaying hepatitis C treatment regardless of fibrosis stage may be detrimental to patients, ya think?  Reuters Health reported: "Mortality is increased in patients with moderate or severe liver disease related to chronic hepatitis C, and progression from mild/moderate to severe disease cannot be predicted reliably." Here is a quote from Dr. Cepeda, a key author of the study; “Fight to treat your patients as early as possible.” Read the rest of the article, here.

However, according to a report released this month from Trio Health, after patients are prescribed HCV therapy insurance companies are denying coverage, interim data from the study showed HCV treatment non-starts are up, from eight percent in 2014, to over 30 percent in 2016, for the most part because of payer coverage denials. The HCV regimens evaluated in the study include the following: Sovaldi®/Harvoni® (Gilead), Viekira Pak™ (Abbvie), Zepatier™ (Merck), Daklinza™ (BMS) and Epclusa® (Gilead). Read commentary on the report here, Trio press release here.

Annals of Internal Medicine, reported high cure rates, with few side effects, in a review article on various FDA approved regimens to treat chronic hepatitis C. Sustained virologic response (SVR) for genotype 1 (using different approved HCV regimens) was reported at over 95%. Sofosbuvir plus velpatasvir  or daclatasvir for 12 weeks in genotype 3 patients without cirrhosis appeared to seem most effective, for geno 3's with cirrhosis, a regimen of velpatasvir-sofosbuvir had higher response rates, the latter is  also highly effective (99% response rate) for genotypes 2, 4, 5, and 6, this summary was published in NEJM Journal Watch, read the full text article; Hepatitis C: Down but Not Out - Oral Direct-Acting Agent Therapy for HCV.

Weekly News Coverage
HEP offers hepatitis C research with daily news, a great place to start learning about HCV.
Over at HepCBC, each Friday a nice summary of news is available, read this weeks: Weekly Bull.

Daily news, updates and more over at Healio.
Check out the following March publications as well.
HCV Next
Healio Gastroenterology
Infectious Disease News

News Re-Cap
Author: Richard Pizzi Family Practice News
Publish date: March 21, 2017 - Hepatitis Outlook Late February 2017
Here’s a quick look at some notable news items and journal articles published over the past month, which cover a variety of the major hepatitis viruses.

Week Ending March 22, 2017
Hepatitis C | MD Magazine
Infectious Disease Special Edition
Don't miss recent articles written by your favorite bloggers over at HEP blogs. is a great site for patient resources and personal stories with daily articles.

In Case You Missed It

MD Whistleblower
Medical Marijuana Use - Ready, Fire, Aim!
Michael Kirsch, MD
Promoting medical marijuana use is hot – smokin’ hot. States are racing to legalize this product, both for recreational and medical use. In my view, there’s a stronger case to be made for the former than the latter.

Presently, marijuana is a Schedule I drug, along with heroin, LSD and Ecstasy. The Food and Drug Administration (FDA) defines this category as drugs with no acceptable medical use and a high potential risk of addiction. Schedule I contains drugs that the FDA deems to be the least useful and most dangerous. Schedule V includes cough medicine containing codeine.

Hepatitis C Foundation
How to Find a Liver Specialist Who Really Knows Hepatitis B
March 22, 2017
By Christine Kukka
If you have chronic hepatitis B or are newly-diagnosed, it’s important to see a liver specialist who has experience with hepatitis B.

Having a specialist with hepatitis B expertise on your team not only safeguards your health, it also lessens the stress of having a chronic liver disease. “My specialist gave me all the possible scenarios, but most importantly, he gave me my life back,” one hepatitis B patient recalled.

Date Released: Mar 8 2017
HCV Management In Liver Transplantation
Dr. Robert Brown discusses management of hepatitis C infection in patients undergoing liver transplantation, Dr. Nancy Sokol hosts.
Listen here...

Learning Activity
Watch - Release Date: 3/15/2017
Hepatitis C: New Paradigms for Evaluation & Management
Dr. Naudia Jonassaint discusses the new paradigms in regards to the evaluation and management of Hepatitis C. She reviews the basic epidemiology & scope of Hepatitis C, appropriate screening for Hepatitis C, basic Hepatitis C treatment options , identification of special populations, and post SVR Monitoring
Quick View, watch here...

Healthy You

Behind The Headlines
Overweight young men 'more likely to get severe liver disease'
"Men who are overweight in their late teens have a higher risk of developing liver cancer in later life, new research suggests," reports ITV News. Swedish researchers also found a link to other serious types of liver disease…

Updates On This Blog
HCV vaccines—back to the future?
Effects of Melatonin on Liver Injuries and Diseases
Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C
Study - Statin use may lead to: Decreased fibrosis and Reduced risk of developing liver cancer
Watch - Hepatitis C Overview
Chronic Hepatitis C And Functional Dyspepsia (FD) - A Feeling Of Discomfort In The Upper Abdomen
HCV - Fatty liver disease and genotype 3
HCV Genotypes/Treatment
Is There A Natural Way To Improve Liver Fibrosis?

Check back for updates, enjoy the rest of your weekend.

Saturday, February 4, 2017

Weekend Reading - Natural History And Conditions Related To HCV

Greetings to all, welcome to this edition of Weekend Reading. Thanks to Henry E. Chang, a quick overview of HCV and related conditions is the focus on the blog today. The good doctor often tweets PDF full text HCV articles on twitter, follow him here.

The Stats
Today, approximately 2.7 million Americans are infected with hepatitis C, with an estimated 130–200 million people worldwide. Of persons infected with hepatitis C, 15-25 percent will recover (spontaneous clearance) and 75-85 percent will become chronically infected.

A Review of the Natural History of Chronic Hepatitis C Infection
The natural history of hepatitis C remains controversial. Among HCV-infected individuals progression to advanced liver disease generally requires decades but is influenced by several host factors. For instance studies have shown factors such as; (age, sex, race, genetics), viral characteristics (genotype), behavioral (smoking, alcohol), metabolic factors (insulin resistance, obesity), and co-infection (Hepatitis B and HIV) may impact the degree of fibrosis and progression to cirrhosis as well as the potential for development of liver cancer. These factors are discussed in a review of the natural history of hepatitis C, published in the 2014 issue of  North American Journal Of  Medicine And Science.

Does Alcohol  Influence Spontaneous Clearance?
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males; Results indicate that abstaining from drinking alcohol may increase the likelihood of spontaneous clearance among women.

Although, chronic infection can be cured about 90% of the time with FDA approved treatments, host factors still determine disease progression in people without viral eradication. As an example, persons with HCV-related cirrhosis, who consume light-to-moderate alcohol, compared to people who do not drink - increase the risk for liver cancer.

But can host factors influence mortality risk in people who successfully clear the virus with HCV therapy?
In an article reviewing a study published in the Journal of Hepatology (2016), Michael Carter writes about the mortality rates among people with HCV who achieve SVR. Again, host factors/health risk behaviors were an important factor for mortality. He writes; Most of the excess mortality was due to drug use or liver cancer. Several modifiable characteristics were associated with subsequent mortality risk, including drug use and heavy alcohol consumption. People without these risk factors – approximately a third of the study population – had survival that matched that of the general population. Here is the article; People with HCV attaining SVR continue to have increased mortality risk but this is due to alcohol and drug use.

Disease Progression
Researchers often reference a unique cohort of HCV patients when describing the natural history of hepatitis C. Never has there been a more perfect natural history study, in that - the known dates of infection were clear and precise. This for the most part is difficult to achieve since the time of acute HCV infection is often impossible to establish.

The somewhat famous and tragic cohort include 704 Irish women (1977-1978) and 917 German women (1978-1979) who were exposed to hepatitis C from contaminated Anti-D immunoglobulin, all from a single source. Researchers have studied the aging population of women at 17, 20, 25 and 35 years after infection.

In the German cohort previous studies suggest low rates of liver disease progression at 20 and 25 years after infection, showing only 0.5% end-stage liver cirrhosis at 25 years after infection, according to an article published in Hepatology 2014;58:49–57.

In the article investigators extended the study to 35 years after infection comprising of 718 patients of the original anti-D cohort.

Mortality at 35 Years After Infection
Figure 4 summarizes the overall mortality of the German HCV cohort at 35 years after infection in relation to the HCV infection status.

In total, 30 patients (4.2%) of the actual study cohort died since 1979. In the group of HCV RNA-negative patients, 10 (3.0%) died, among them 2 who were classified as inoculated patients without hepatitis, 7 with spontaneous recovery from HCV infection, and 1 with SVR after treatment who died of a malignant disease other than HCC.

In the group of HCV RNA-positive patients, 20 (5.3%) died, among them 9 (1.3%) who succumbed to definite HCV-related end-stage liver complications, such as esophageal variceal bleeding or hepatic coma. The remaining 11 HCV RNA-positive patients (1.5%) died from additional non-liver-related causes, such as cardiac failure, nonliver malignancy, apoplectic insult, or accident.

Click on image to enlarge

Conclusion: The present study provides further evidence for a mild, but significant, disease progression at 35 years after infection in the German HCV (1b)-contaminated anti-D cohort. Patients with self-limited HCV infection or SVR after antiviral treatment were protected from progressive liver disease and showed the best clinical long-term outcome.
Review the article; Evaluation of liver disease progression in the German HCV (1b)-contaminated anti-D cohort at 35 years after infection.

Of Interest
New study launched to discover how “super” immune system can prevent hepatitis C
Scientists from Trinity College Dublin are seeking volunteers who were exposed to anti-D contaminated with hepatitis C virus (HCV) between 1977 and 1979 as they attempt to discover why some people are naturally protected from HCV infection, while others are not.

Extrahepatic Manifestations
Review this series of great articles on the extrahepatic manifestations of HCV.
Published in Journal of Advanced Research
Volume 8, Issue 2, March 2017, Pages 85–87

Index Of Articles
HCV - Fatty liver disease and genotype 3
In this post a collection of journal articles and videos reviewing HCV and fatty liver disease is offered; with a focus on individuals afflicted with both conditions. In addition given the development of steatosis (abnormal levels of fat in your liver) is higher in people with HCV and genotype 3, links are provided to current therapies in this difficult to cure genotype. Finishing off with several tips to help keep your liver healthy.

An Overview Of Hepatitis C Medications
Treatment Options in Hepatitis C — The Current State of the Art
By Stefan Zeuzem published in the January 2017 issue of Deutsches Ă„rzteblatt International
This review is based on relevant publications retrieved by a selective literature search, and particularly on studies and reviews concerning the course and treatment of hepatitis C.
Begin here...

Clinical Care Options
How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management
Mark S. Sulkowski MD - 1/31/2017
I am really enjoying treating patients with HCV infection in this era of highly effective direct-acting antivirals (DAAs). Think about it: Our patients present with life-threatening, chronic infections, and we cure more than 95% of them with few adverse events. Other than insurance challenges, what’s not to love?
Despite the relatively easy road to cure with modern therapy in most of my HCV-infected patients, I can think of 2 recent patients who presented challenges: a patient with relapse and resistance associated substitutions (RASs) after treatment with a DAA and a patient with genotype 3 HCV infection and severely reduced renal function...
*Free registration required to view article

Achieving A Cure
Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis
For patients with hepatitis C virus (HCV) infection and biopsy-proven cirrhosis, sustained viral response (SVR) is associated with a reduction in critical events, both liver and non-liver related, according to research recently published in Gastroenterology.

Helpful Links

HCV Advocate
Clinical Trials Reference Guide
Users can search for a hepatitis C clinical trial by category (genotype), or learn how to evaluate a clinical trial and become familiar with commonly used terms. HCV Advocate offers an easy to navigate HCV Medications Blog as well, organized by HCV genotype.

2017-HCV Genotypes/Treatment
Offered on this page of the blog is research updates with a focus on treating HCV according to genotype using FDA approved and investigational medicines. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities. 

Hopefully, this small summary will leave you with a better understanding of the natural history of  hepatitis C, conditions outside the liver (Extrahepatic Manifestations) and medications used to treat the virus.   

May you all enjoy the rest of your weekend.

Sunday, November 6, 2016

HCV Reading: AASLD Key Abstracts Reviewed By Pacific Hepatitis C Network

HCV Weekend Reading: Week In Review
Hello everyone, here is a look back at last weeks publications, headlines, and hot topics including today's news with updates as the day progresses.

What's New
This month Pacific Hepatitis C Network (PHCN) just started a news in review newsletter. Don't miss a two part blog post summarizing key HCV abstracts that will be presented at next weeks American Association for the Study of Liver Diseases 67th annual meeting. Next read through Hep C Tip News, with information about the latest drugs to treat hepatitis C. Finally stay updated by joining Pacific Hepatitis C Network's mailing list.

AASLD 2016 Updates On This Blog
AASLD 2016 Conference Updates

Digest Of News
In addition review important HCV headlines in the latest edition of The Weekly Bull online over at HepCBC.

Follow the links provided further down this post to review highlights from both Canadian publications.

Health Review - A User's Guide to the Common Cold
Johns Hopkins Fall/Winter 2016 Health Review is out, with expert advice on how to survive the flu and cold season; A User's Guide to the Common Cold. Another article of interest; Understanding Inflammation about chronic inflammation and its effects on the body is featured in the Spring/Summer 2016 issue.

In Case You Missed It
The November index of HCV newsletters was recently updated to include three new publications, begin here.

Hot Topic - In Today's News
Nov 6
Buyers clubs for cheaper drugs help fight hepatitis and HIV
A Indian-made course of treatment for the liver-destroying disease hepatitis C, meanwhile, can be had for around 1,000 pounds against a list price for branded drugs of around 35,000.Gilead is also a leading producer of patented hepatitis C drugs, along with Merck and AbbVie.

Published Nov 2
Watch - An Introduction to Access to Generic Hepatitis C Medicines
Following the success of the first two webinars in the Knowledge for Change series covering access to diagnostics and medicines, we were pleased to deliver the next in the series, ‘An Introduction to Accessing Generic Hepatitis C Medicines’ on 1 November. The webinar explored the generics landscape for hepatitis C with discussions on legalities, quality and performance of generics medicines as well as providing examples of how people across the globe are accessing them.

Todays' News
Nov 7
Bayer applies for Regorafenib authorization to treat liver cancer
German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.

Nov 6
Lawmakers Hear From Organ Harvesting Investigators
In 2006 international human rights lawyer David Matas and former Crown attorney and cabinet minister David Kilgour first released an initial investigative report into allegations of live organ harvesting in China; Kilgour-Matas Report. Read their latest report, released in June, at a House of Commons hearing on Nov. 3, along with other articles on recent advocacy efforts and government solutions.

Cairns leads regional Queensland in roll out of new hepatitis C drug
“In Australia there’s about 250,000 people with hepatitis C and we think, since the medication has become available on March 1, we’ve treated nearly 40,000 people Australia-wide.”

NM aims to control hepatitis C costs

Albuquerque Journal
Last year, the New Mexico Medicaid program spent $36.5 million for hepatitis

Recent News and Research
Nov 7
​All Genotypes​
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
Chronic hepatitis C is a major reason for development of cirrhosis and a leading cause for liver transplantation. The development of direct-acting antiviral agents (DAA) offered new therapeutic options for patients with advanced cirrhosis and liver graft recipients. This review gives a high topical summary of most current therapeutic options of DAA-based antiviral therapy in patients with hepatitis C virus associated cirrhosis before and after liver transplantation.

Nov 4
Shorter Hep C Regimens Hot Topic at the Liver Meeting
Medscape-40 minutes ago
BOSTON — Shortening the length of curative regimens for hepatitis C treatment will be one of the hot topics here at The Liver Meeting 2016. One study likely to ...
Reported by Jules Levin
IDWeek Oct 26-30
New Orleans 2016

Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies

Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment
The prevalence of mental health disease (MHD) among patients with chronic hepatitis C virus (HCV) can be high. However, patients with MHD may be marginalized with respect to HCV therapy and MHD is one of the most frequently cited reason for exclusion from HCV therapy. HCV therapy has evolved from interferon-based to directly acting antiviral (DAA)-based therapy with excellent tolerability and efficacy. Our study found that baseline MHD did not impact efficacy nor treatment adherence to sofosbuvir-based therapy. Furthermore, we found that Becks Depression Inventory scores improved with sofosbuvir-based therapy, suggesting that HCV treatment with the newer DAA therapies may have additional mental health benefits.​

Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections
Alcohol use disorder (AUD) and hepatitis C virus (HCV) infection frequently co-occur. AUD is associated with greater exposure to HCV infection, increased HCV infection persistence, and more extensive liver damage due to interactions between AUD and HCV on immune responses, cytotoxicity, and oxidative stress. Although AUD and HCV infection are associated with increased morbidity and mortality, HCV antiviral therapy is less commonly prescribed in individuals with both conditions. AUD is also common in human immunodeficiency virus (HIV) infection, which negatively impacts proper HIV care and adherence to antiretroviral therapy, and liver disease​...

Prevention of Progression to Cirrhosis in Hepatitis C With Fibrosis
Are direct-acting anti-virals cost-effective treatment for patients with HCV infection with liver fibrosis who are at high risk of progression to cirrhosis?

Evidence shows value of treating all stages of chronic HCV
Evidence from 38 studies, involving 73,861 patients, showed a significant mortality benefit of achieving SVR in patients with all stages of fibrosis. Long-term studies with follow-ups of five to 12 years suggested that, particularly among non-cirrhotic patients, there was a significant decrease in mortality in SVR versus non-SVR groups.

MRE, MRI-PDFF best other techniques for detection of fibrosis, steatosis
Recent findings show magnetic resonance elastography was more accurate for detecting liver fibrosis vs. transient elastography, and MRI-based proton density fat fraction was more accurate than controlled attenuation parameter for detecting steatosis, in patients with biopsy-proven nonalcoholic fatty liver disease.​

Biopsy Not Needed to Track Impact of Direct-Acting Antivirals
Noninvasive technology can accurately measure liver stiffness and track progress in liver disease cure.

News In Review
The Pacific Hepatitis C Network
The Pacific Hepatitis C Network’s mission is to strengthen the capacity of individuals and organizations throughout British Columbia to prevent HCV infections and improve the health and treatment outcomes of people with HCV.

One of its projects is the Hepatitis C Treatment Information Project your web-based hepatitis C treatment information toolkit for entering into that world and building your understanding about hep C treatment.

The Pacific Hepatitis C Network‘s News in Review Newsletter
November 5, 2016
Welcome to the Pacific Hepatitis C Network (PHCN)‘s very first hepatitis C news in review newsletter. This is where we review all of the major issues and events around hepatitis C and hep C treatments. It is an email that includes links to all of our recent blog posts—including the blog post about the big news surrounding the hep C treatment Epclusa (generic name: sofosbuvir/velpatasvir).

Epclusa (generic name: sofosbuvir/velpatasvir), developed by Gilead Sciences Canada, Inc., just passed its Common Drug Review with the release of the Canadian Drug Expert Committee (CDEC) Final Recommendation. Click here to read more about their recommendation sent to the provinces and territories to help them decide on whether or not to cover the treatment and how to cover it.

In October, Daryl Luster wrote two blog posts for the Pacific Hepatitis C Network. Daryl is a hep C advocate who is PHCN’s president, a member of the Executive Steering Committee for Action Hepatitis Canada (AHC), a counselor for the Help-4-Hep helpline, and the administrator of multiple peer support groups. In 2010, Daryl was cured of hep C while participating in a clinical trial. The two blog posts he wrote were:

DAAs: Long Term Effects
AHC BC Regional Meeting: October 18-19

The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, will be held in a week. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, will be hosting the meeting and, as always, the meeting promises to be exciting.

To celebrate the meeting and all of the amazing discoveries that will be presented, the Hepatitis C Treatment Information Project wrote the following blog posts summarizing and highlighting some of what will be presented about hep C treatments:

The Liver Meeting 2016 Hep C Abstract Highlights (Part1)
The Liver Meeting 2016 Hep C Abstract Highlights (Part2)
Live Stream Sessions from The Liver Meeting 2016

The Basics Series by the Hepatitis C Treatment Information Project is a series of blog posts about the very basics about hep C and hep C treatments. So far, the series has five issues, entitled the following:
Hepatitis C Genotypes: The Basics
Pan-Genotypic Hepatitis C Treatments: The Basics
To treat or to wait? That may be the question with hep C treatment.
Treatments Covered by BC PharmaCare for Hep C Genotypes 1a/1b
Treatments Covered by BC PharmaCare for Hep C Genotypes 2-6

For more information about the topics in this newsletter, please click on the links, visit PHCN’s Hepatitis C Treatment Information Project, or email us.

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

Weekly Bull
Friday, November-4-16 
News in Brief

Pan-Genotypic Hep C Drug Epclusa™ Recommended for PharmaCare Coverage by CADTH
November 4, 2016
Epclusa™, a Direct-Acting-Antiviral combo for ALL GENOTYPES of Chronic Hepatitis C, received approval from CADTH on October 28, 2016. This combo of (generics) sofosbuvir and velpatasvir, from Gilead Sciences, was recommended by CADTH’s Canadian Drug Expert Committtee (CDEC) for reimbursement by provincial and territorial PharmaCares.

BC Ministry of Health’s Refusal to Reimburse Critical Drug “Zaxine™” for Hepatic Encephalopathy
November 4, 2016
BC Ministry of Health sent a puzzling reply to HepCBC’s request for reimbursement of hepatic encephalopathy drug rifaximin (Zaxine™). BC is the only province/territory which does not cover it; many of BC’s End Stage Liver Disease (ESLD) patients are suffering from preventable brain damage because of this. This drug has been shown to be of great benefit to patients suffering from ESLD, either in combination with lactulose, or instead of lactulose in cases where lactulose does not work. Nevertheless, BC is still refusing to cover it.

Who sets the maximum price allowed for patent medicines in Canada, including hep C treatments?
November 4, 2016
The “Patented Medicine Prices Review Board” (PMPRB) does! PMPRB asked patient groups for feedback on proposed changes to PMPRB’s mandate. In our submission, HepCBC asked for maximum pricing to reflect “prevalence” of a disease (how many people have it), because the more treatments you can sell, the more you can lower your price and still make the same or better profit. We advocated for pricing which is more in line with European rather than American prices. We also advocated for an “Equitable Profit Margin”. We said it is not so important to patients if Research and Development is done in Canada as long as clinical trials are conducted here. Read HepCBC’s full (8 page) submission:

These researchers think they have a solution to the global crisis in drug prices
November 4, 2016
Jerome Zeldis remembers exactly how he felt when he heard about the $84,000 price tag on a powerful new hepatitis C treatment three years ago. “I was somewhere between annoyed and outraged,” recalled Zeldis, the former chief medical officer of the biotech juggernaut Celgene. So he has started Trek Therapeutics as a public benefit corporation – a relatively new type of corporate structure that places public welfare on equal footing with profit.

DAA Combination Treatment Fast and Effective for Hepatitis C
November 3, 2016
Sofosbuvir, velpatasvir, and voxilaprevir for 8 weeks does the trick across all genotypes, treatment experienced, DAA relapse or cirrhosis! Two phase 2 studies of combination direct-acting antiviral agent (DAA) treatments were published recently in Gastroenterology. They were accompanied by an editorial simply titled “Hepatitis C Therapy: Game Over!”

What Are the Out of Pocket Costs for Harvoni, Viekira Pak and Epclusa under Medicare Part D?
November 3, 2016
We often get asked this question by American visitors to our site, and we hope this page will help provide the answers you need. Not all drugs are covered by Medicaid but there are “coupons” that you can use. The information is from GoodRX. This is for the USA only.

Vietnam vets urged to receive hepatitis C testing
November 2, 2016
American Legion Post 1619 is working on a statewide awareness campaign and urging all Vietnam-era veterans to get tested for hepatitis C. Two free clinics are scheduled for Nov. 4 and 5 in Morrisonville. MORRISONVILLE NY — The boot camp ritual was robotic in its precision. Soldiers lined up for their vaccination shots. Needles were outdated, “jet guns” were in, and soldiers received high pressure blasts of an 18-drug cocktail before being shipped off.

Acute hepatitis after heavy energy drink use ‘a warning to the consumer,’ liver specialist says
November 1, 2016
Construction worker relied on 4 to 5 bottles a day to get through his shift A construction worker who consumed an excessive amount of energy drinks developed a rare case of acute hepatitis, say doctors who want patients to know about the potential risks to the liver from such over-consumption.

HCV reinfection common in MSM with HIV
November 1, 2016
In a retrospective study, researchers found that hepatitis C virus reinfection is common among HIV-positive men who have sex with men after successful treatment and spontaneous clearance. “A subsequent high incidence of HCV reinfection has been reported regionally in men who both clear the infection spontaneously or who respond to treatment.

Recurrent viremia infrequent in hepatitis C
November 1, 2016
The prevalence of recurrent viremia was low among patients with hepatitis C who achieved sustained virologic response, data from a recently published study demonstrate. Among those patients who did experience late recurrent viremia, most had HCV reinfection. (HCV reinfection common in MSM with HIV).

Two genes linked to increase in immunity to hepatitis C after childbirth, study shows
October 31, 2016
Alternative forms of two genes are associated with a boost in immunity to hepatitis C after childbirth, a study led by a Nationwide Children’s Hospital physician-researcher shows. At three months postpartum, the number of viruses circulating in the blood declined sharply in most women who carried particular versions of IFNL3 and HLA-DPB1 genes. Mothers lacking these gene variants experienced little change in viral levels after delivery.

Tampa Bay woman with Hepatitis C reduces co-pay for treatments with coupon
October 31, 2016
PASADENA, FL (WFLA) — The FDA has approved several new cures for people fighting chronic diseases, but the problem is, many people can’t afford the drugs and insurance companies will cover only the sickest patients. That includes a drug now on the market for people with Hepatitis C called Harvoni — a pill that patients take for 8 to 12 weeks. Wendy Latorre, of Pasadena, says when she heard about the drugs she was extremely hopeful. “And then she found out the cost!

Dating after Hepatitis C: Hope on the horizon for the 1 in 30 boomers estimated to be infected
October 30, 2016
Baby boomers are 6 times more likely to be infected than other adults. We need to talk about testing and treatment. Recently I went on a first date — a stroll in a city park — that went rather well. We had so much in common, from a love of reading to a history of youthful troublemaking. If I wasn’t convinced already he was someone I could relate to, my new friend shared that he’d been cured of Hepatitis C. I could hardly believe it.

Why all those discarded needles are signs of progress for HIV, Hep C in Southern Interior
October 29, 2016
THOMPSON-OKANAGAN – Nearly 400 new Hepatitis C cases and as many as 15 HIV cases were recorded by Interior Health last year, and most were caused by injection drug use. The numbers may seem surprisingly high, but are average compared to recent years, according to senior medical health officer Dr. Trevor Corneil, who says they’ve actually been on an overall downward trend over the past 15 years with the advent of harm reduction strategies.

Generic hepatitis C drugs purchased online achieve high cure rates
October 28, 2016
Use of generic versions of direct-acting antivirals resulted in very high cure rates for people who obtained the products through three buyers’ clubs, indicating that the generic products are effective, according to three presentations at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week. People who purchased the drugs were cured of hepatitis C at a cost of around $700-$900 in South-East Asia and Eastern Europe.

I have a little news of my own, I just found out my son is getting married! Enjoy the rest of your weekend folks.


Sunday, September 25, 2016

New Perspectives in HCV Infection

October 2016 Volume 65, Issue 1, Supplement, S1-S156
Journal Of Hepatology

New Perspectives in HCV Infection
Edited by Thomas Berg, Xavier Forns


Assessment of HCV Disease
Benjamin Maasoumy, Johannes Vermehren
Published in issue: October 2016

Treatment and Remaining Challenges
Reversion of disease manifestations after HCV eradication
Adriaan J. van der Meer, Marina Berenguer
Published in issue: October 2016

Norah A. Terrault, Tarek I. Hassanein
Published in issue: October 2016

HCV Perspectives
Jordan J. Feld, Graham R. Foster
Published in issue: October 2016
Full-Text HTML PDF

Future landscape of hepatitis C research – Basic, translational and clinical perspectives
Darius Moradpour, Arash Grakoui, Michael P. Manns
Published in issue: October

Saturday, July 23, 2016

Weekend Reading: Coffee can play a role in reducing risks of cancer and diabetes

Coffee can play a role in reducing risks of cancer and diabetes

Good day folks, in this issue of "Weekend Reading" we point you to a podcast over at ABC Radio on the many health benefits of drinking coffee, hosted by Dr. Kruszelnicki.
Topics covered in the two part program include the effect of caffeine on; liver cancer, type II diabetes, prostate cancer, oral cancer, and heart disease.

But what about the side effects of drinking coffee, good or bad?

There is a body of evidence that some of the side effects of coffee may actually be good for you, and they appear to have nothing to do with caffeine. But Dr Karl Kruszelnicki's grind is the observational studies that make up the 'statistics' behind the health benefits.

Listen to the podcast or read the transcript;

Coffee is now good for us—or is it?
Part One - Listen here
July 12 2016
Yes, it is a drug, and so we should remember the words of Paracelsus, 'all drugs are poisons, what matters is the dose.' Based on the fact that coffee has been used widely for over a millennium, we would expect its bad side-effects would be fairly minimal—so long as we don't take too much.
Read the transcript

Part Two - Listen here
July 19,2016
Coffee can play a role in reducing risks of cancer and diabetes
It seems that beside caffeine, there are other natural chemicals in coffee that can help with medical conditions. With regard to liver cancer, two chemicals, kahweol and cafestrol, have direct cancer protection and anti-inflammatory properties. They seem to 'upregulate biochemical pathways in the liver that protect the body from toxins, including aflatoxin and other carcinogenic compounds'.
Read the transcript


Saturday, June 11, 2016

Weekend Reading - Treating HCV genotype 4 and Treating HCV patients with diabetes & obesity

Welcome To Weekend Reading
Greetings, hope everyone is enjoying a lovely Saturday. Before heading out to plant a seed, yes one seed that was given to Nana by the little people, I wanted to add a few June updates for your reading pleasure this weekend. 

In this issue of "Weekend Reading" I suggest a new learning activity, as well as some great articles written by a small group of dedicated bloggers who share their personal stories about living with and treating HCV.

We begin with this awesome video presentation; "Eliminating the HCV Scourge: Together We Can Do It," released last month over at ViralEd.

Sit back and watch HCV experts Nezam H. Afdhal, MD and Mark Sulkowski, MD discuss the most critical aspects of HCV prevention, management and treatment, here are a few highlights to get you started;

Treating HCV: patients with diabetes & obesity
Treating HCV genotype 4
Treating HCV: intravenous drugs users

Launch the on-demand program, here.

In Case You Missed It
Nezam H. Afdhal, MD 
25 Years From Discovery To Cure: The Hepatitis C Story
Dr. Afdhal discusses how discovery of the virus lead to understanding the global epidemiology and modes of spread of hepatitis C and the recognition that it was the commonest cause of cirrhosis, liver cancer and need for liver transplantation.
Begin, here....

Regimens for treating genotype 2, 3, 4, 5, or 6 HCV infection

New At Clinical Care Options
Non–Genotype 1 HCV Now and in the Near Future
Posted June 9   
In this downloadable slideset, Jordan J. Feld, MD, MPH, and Andrew J. Muir, MD, review current and emerging regimens for treating patients with genotype 2, 3, 4, 5, or 6 HCV infection.
Download slides here, view all updates here...
** Free registration required

Special NVHR Conference Call: A National Strategy for the Elimination of Hepatitis B & C
This call was held on Monday, May 16, 2016 at 2 pm Eastern. It has been archived, to access the slides, please click here.

Publication Updates Around The Web

HCV Advocate Monthly Pipeline Update
Each month HCV Advocate presents an update on the HCV Pipeline written by Alan Franciscus. Review study results with commentary from the following pharmaceutical companies that make hepatitis C medications; AbbVie, Gilead, Janssen (Achillion/Alios), Merck and Regulus.

A note from Alan Franciscus
Within this section, I will list the genotype(s) being studied and the phase of the study with a brief recap of the study . You will note that many of the drugs or combinations of drugs are pan-genotypic—that is they work on many or most of the HCV genotypes . Many of the drugs listed have been updated with the latest information from the Liver Meeting 2015 and the International Liver Congress 2016 .
Begin, here..

Just So You Know
The HCV Advocate produces two monthly newsletters;
HCV Advocate is posted on the first of the month and the Mid-Month Edition is published on the 15th of the month.

The Monthly HCV Advocate: Monthly columns include “HealthWise,” written by Lucinda Porter, RN, “What’s New,” written by Alan Franciscus, and “Snapshots,” written by Alan Franciscus.

The Mid-Month Edition: Monthly columns include “Snapshots” by Alan Franciscus, “What’s New” by Alan Franciscus, and updates of our HCV drug pipeline.

Monthly Publications:
Hepatitis C Newsletters
On this blog each month an index of HCV Newsletters is posted with noteworthy updates from around the web. 

Blog Updates

With direct acting antivirals approved for all Australians with hepatitis C, regardless of severity of damage, the figures are looking good!
June 10, 2016 • By Grace Campbell
It's very exciting to be part of this first wave of successful treatment. I didn't think I could imagine Australia free of hepatitis C, but maybe it's a possibility. We can but hope.

Of Interest
June 6

#3LiverTransplants: First Recovery (Part 1)
June 9, 2016 • By Colton Cooper
Colton Cooper shares his inspirational story about his third liver transplant
​Although I had a fresh ten-inch scar across my chest, multiple IV lines running through my veins, taking a ton of medicines that I can’t pronounce and stuck lying in a hospital bed, I felt healthier than I had been in a very long time.
Begin, here...  

Reducing Medical Costs
By Lucinda K. Porter, RN - June 9, 2016
I am insured though the Affordable Care Act (ACA), also known as Obamacare. Before ACA, I was uninsurable because of hepatitis C. However, the Health Insurance Portability and Accountability Act (HIPAA) allowed me to keep my insurance plan when I left Stanford Medical Center.

The Quiet Creeping of Corruption
June 9, 2016 • By Greg Jefferys
It looks likely that in 2016 generic Hepatitis C medicines will reduce Gilead's profits by a few billion dollars. In the scheme of things, for a company that makes tens of billions of dollars profit each year it is not a big thing but for greedy people and greedy, rapacious corporations, every dollar counts.

Hepatitis C, Asparagus and Tending Our Gardens With Meditation
June 7, 2016 • By Matt Starr
I meditate to settle into myself, to heal my overly busy mind and body from the ravages of liver disease.  Sitting with awareness only on the breath, you can discover health of mind, body, and spirit.

When the Pain Won’t Go Away
June 6, 2016 • By Kimberly Morgan Bossley
My movement throughout my house is slower as the hardwood floors under my feet cause me to be overly cautious with my steps. Throughout my journey with hep C, I have lost feeling in my feet. Sure I have nerve pain, but there is a numbness that warrants me to insure each step is planted firmly.

How Not to Feel Stupid with Hepatitis C
By Karen Hoyt - June 9, 2016
When you get diagnosed with hep C, you don’t know a lot about what’s going on. Sure, you get on websites like this one and try to get some information – (loud...
Begin, here...

Sodium and the Liver: What those with Hepatitis C Should Know
By Jenelle Marie Davis - June 9, 2016
What does the liver do? The liver’s primary purpose is to clean the blood. Blood needs to be cleaned both because the body naturally produces some toxins and because some of the...

Strategy: Next treatment
By Rick Nash - June 8, 2016
How it helps combat the treatment: When the first treatment failed there wasn’t anything in the near future. But there is always hope, at the time medical advances in genomics were finding...

One in Three People Worldwide Has Had Hepatitis B, So Why Do We Feel So Alone?
By Christine Kukka - June 8
Hepatitis B is the global pandemic no one talks about, yet one in three people worldwide has been infected. In 2013, hepatitis B and C together was the seventh-leading cause of death worldwide, with hepatitis B causing 780,000 deaths annually.
Begin, here..

Gastroenterology Special Issue on Alcoholic vs Non-Alcoholic Fatty Liver Disease
By Dr. Kristine Novak - June 9
A special issue of Gastroenterology is devoted to comparing alcoholic vs nonalcoholic fatty liver disease. In an introduction to the issue, Arun Sanyal et al write that alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have much in common, including histologic features and activation of pathways involved in their pathogenesis.
Begin, here..

Published on Jun 9, 2016
Boise Dr. Magni Hamso with Terry Reilly Health Services talks about hepatitis C

Idaho forced to ration costly hepatitis C cure
By Cynthia Sewell
June 11
Limited funds and high demand have forced many states to restrict coverage to those patients with the most severe liver scarring, called fibrosis.

“I certainly sympathize with the people who have to create these thresholds or these qualifications for treatment,” Box said. “I do not think anybody is withholding therapy out of any other motive than they are in charge of a budget, and these are budget-busting costs.”
Hepatitis C patients also draw limited sympathy because of the self-inflicted nature of the disease. That means treatment costs draw more resistance than, say, the cost of treating cancer, Box said.
Begin, here....

2,436 patients with hepatitis C in one Alabama ER since implementing widespread testing in 2013
Hepatitis C testing in the emergency department at the University of Alabama at Birmingham Hospital has discovered 2,436 positive cases since testing began in September 2013.
Begin, here..

Have a safe weekend.